Cancer最新文献

{"title":"Karkinos in ancient medicine: More than just fatal cancer","authors":"Michele Augusto Riva MD, PhD","doi":"10.1002/cncr.35741","DOIUrl":"10.1002/cncr.35741","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to “Karkinos in ancient medicine: More than just fatal cancer”","authors":"Konstantine Panegyres PhD","doi":"10.1002/cncr.35742","DOIUrl":"10.1002/cncr.35742","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3–targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","authors":"Jacob M. Sands MD,&nbsp;Stéphane Champiat MD, PhD,&nbsp;Horst-Dieter Hummel MD,&nbsp;Kelly G. Paulson MD, PhD,&nbsp;Hossein Borghaei DO,&nbsp;Jean Bustamante Alvarez MD,&nbsp;David P. Carbone MD, PhD,&nbsp;Jennifer W. Carlisle MD,&nbsp;Noura J. Choudhury MD,&nbsp;Jeffrey M. Clarke MD,&nbsp;Shirish M. Gadgeel MD,&nbsp;Hiroki Izumi MD, PhD,&nbsp;Alejandro Navarro MD,&nbsp;Sally C. M. Lau MD,&nbsp;Philip E. Lammers MD,&nbsp;Shuang Huang PhD,&nbsp;Ali Hamidi MD,&nbsp;Sujoy Mukherjee MD,&nbsp;Taofeek K. Owonikoko MD, PhD","doi":"10.1002/cncr.35738","DOIUrl":"10.1002/cncr.35738","url":null,"abstract":"<p>Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer, tarlatamab 10 mg every 2 weeks achieved durable responses and encouraging survival outcomes. Analyses of updated safety data from the DeLLphi-301 trial demonstrated that the most common treatment-emergent adverse events were cytokine release syndrome (53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), and an emia (30%). Cytokine release syndrome was mostly grade 1 or 2 in severity, occurred primarily after the first or second tarlatamab dose, and was managed with supportive care, which included the administration of antipyretics (e.g., acetaminophen), intravenous hydration, and/or glucocorticoids. Other treatment-emergent adverse effects of interest included neutropenia (16%) and immune effector cell-associated neurotoxicity syndrome and associated neurologic events (10%). Given that tarlatamab is the first T-cell engager approved for the treatment of small cell lung cancer, raising awareness with regard to the monitoring and management of tarlatamab-associated adverse events is essential. Here, the authors describe the timing, occurrence, and duration of these adverse events and review the management and risk-mitigation strategies used by clinical investigators during the DeLLphi-301 trial.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer","authors":"Sirui Tan MD,&nbsp;Mingyang Feng MD,&nbsp;Nan Zhou MD,&nbsp;Shunyu Zhang MD,&nbsp;Cheng Yi MD,&nbsp;Hongfeng Gou MD","doi":"10.1002/cncr.35726","DOIUrl":"10.1002/cncr.35726","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aims to explore the genetic characteristics of biliary tract cancer (BTC), with a particular focus on the impact of DNA damage response and repair (DDR) genes on clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 180 patients with BTC and next-generation sequencing data were retrospectively analyzed. Clinical outcomes were compared between DDR-positive and DDR-negative groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>DDR mutations were found in 28.3% of patients, with ATM (7.8%), BAP1 (5.6%), and BRCA2 (3.3%) being the most common. DDR-positive patients receiving first-line platinum-based chemotherapy (<i>n</i> = 73) had a significantly higher objective response rate (50.0% vs. 14.9 %; <i>p</i> = .001), longer median progression-free survival (mPFS) (7.7 vs. 3.8 months; <i>p</i> = .001) and longer median overall survival (28.6 vs. 11.9 months; <i>p</i> &lt; .001). Multivariate analysis confirmed that deleterious DDR gene mutations were independently associated with prolonged mPFS (hazard ratio [HR], 0.37; 95% CI, 0.20–0.67; <i>p</i> &lt; .001) and median overall survival (mOS) (HR, 0.19; 95% CI, 0.08–0.46; <i>p</i> &lt; .001). In 56 patients receiving immunotherapy combined with chemotherapy, DDR-positive patients had a significantly higher overall response rate (45% vs. 8.3%; <i>p</i> = .001), longer mPFS (7.7 vs. 3.8 months; <i>p</i> = .009), and longer mOS (12.7 vs. 8.8 months; <i>p</i> = .011). Multivariate analysis showed that the presence of deleterious DDR gene mutations was associated with significantly longer mPFS (HR, 0.34; 95% CI, 0.16–0.73); <i>p</i> = .005] and mOS (HR, 0.23; 95% CI, 0.08–0.62; <i>p</i> = .004).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Deleterious DDR gene mutations are associated with improved clinical outcomes in patients with BTC treated with platinum-based chemotherapy or immunotherapy combined with chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Historical redlining and survival among children, adolescents, and young adults with cancer diagnosed between 2000–2019 in Seattle and Tacoma, Washington","authors":"Kristine A. Karvonen MD, MS,&nbsp;David R. Doody MS,&nbsp;Dwight Barry PhD,&nbsp;Kira Bona MD, MPH,&nbsp;Lena E. Winestone MD, MSHP,&nbsp;Abby R. Rosenberg MD, MS, MA,&nbsp;Jason A. Mendoza MD, MPH,&nbsp;Stephen M. Schwartz PhD, MPH,&nbsp;Eric J. Chow MD, MPH","doi":"10.1002/cncr.35677","DOIUrl":"10.1002/cncr.35677","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Historical redlining has been associated with inferior survival in adult-onset cancers. However, its relationship with pediatric, adolescent, and young–adult-onset cancer outcomes is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study identified incident cancer among individuals &lt;40 years of age living in Seattle and Tacoma between 2000–2019 via the population-based Cancer Surveillance System. The authors determined case redlining status using Home Owners’ Loans Corporation data overlaid with 2000 and 2010 census tracts. Kaplan–Meier methods and multivariable Cox proportional hazards models were used to determine 5- and 10-year overall survival and hazard ratio (HR) of death according to redlined status. Cox models adjusted for patient and tumor characteristics and area-level poverty; interaction between redlining and area-level poverty was also assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 4355 cases (median age at diagnosis 32 years), overall survival at 5 years was lower (85.1%; 95% confidence interval [CI], 83.5%–86.5%) among individuals residing in redlined neighborhoods compared with those in unexposed neighborhoods (90.3%; 95% CI, 89.0%–91.5%). Survival differences persisted at 10 years. The unadjusted hazard of death for redlined exposed individuals with cancer was higher than redlined unexposed (hazard ratio [HR], 1.62; 95% CI, 1.39–1.89). In the fully adjusted model, mortality remained higher for redlined cases (HR, 1.32; 95% CI, 1.12–1.56). There did not appear to be effect modification from area-level poverty in the relationship between redlining and death (<i>p</i> = .49).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among young individuals with cancer, residence at diagnosis in previously redlined neighborhoods was associated with lower survival compared with those residing in nonredlined neighborhoods, supporting the hypothesis that structural racism exerts persistent effects on contemporary health outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abuse potential and analgesic efficacy of intravenous hydromorphone bolus administration among hospitalized patients with cancer pain: A double-blind, double dummy, randomized crossover trial","authors":"Joseph A. Arthur MD,&nbsp;Akhila Reddy MD,&nbsp;Uday Popat MD,&nbsp;Josiah Halm MD,&nbsp;Nicole Vaughan-Adams MSN, RN,&nbsp;Alan Myers PhD,&nbsp;Peiying Yang PhD,&nbsp;Aline Rozman De Moraes MD,&nbsp;Raul Laureano BS,&nbsp;Irma Lopez-Quinones BSN, MS, RN,&nbsp;Diana Urbauer MS,&nbsp;David Hui MD,&nbsp;Eduardo Bruera MD","doi":"10.1002/cncr.35723","DOIUrl":"10.1002/cncr.35723","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There is much concern that opioids administered as intravenous (iv) bolus for pain relief may inadvertently increase their risk for abuse. However, there is insufficient data to support this. The authors compared the abuse liability potential, analgesic efficacy, and adverse effect profile of fast (iv push) versus slow (iv piggyback) administration of iv hydromorphone among hospitalized patients requiring iv opioids for pain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this double-blind, double dummy, randomized, 2 × 2 crossover trial, patients with ≥4 cancer-related pain were randomly assigned to receive either iv hydromorphone 1 mg administered over 2 minutes (fast iv push) or 15 minutes (slow iv piggyback) during the first treatment period. Participants crossed over to receive the alternate treatments during the second period after a 6-hour washout period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eighty-three eligible patients were allocated to slow–fast (42, 51%) or fast–slow (41, 49%). Both treatments produced low abuse potential scores with no difference between them (mean peak Drug Effect Questionnaire “drug liking” subscale of fast [24.00] vs. slow [24.34], <i>p</i> = .82). A total of 92% and 94% of slow and fast iv hydromorphone recipients, respectively, had similar improvements in pain scores over 120 minutes (odds ratio, 0.67; 95% confidence interval, 0.06–5.82, <i>p</i> = .65). Drowsiness was more frequent with the fast than the slow rate (50% vs. 29% at 15 minutes [<i>p</i> = .03] and 52% vs. 31% at 60 minutes [<i>p</i> = .03]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Slow iv hydromorphone infusion resulted in similar abuse liability potential and pain improvement but less sedation than fast injection. These findings, taken together, suggest that the slow infusion may be considered as a first-line modality for iv opioid administration in hospitalized patients requiring intermittent opioids for pain.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system","authors":"Leah M. Marcotte MD, MS,&nbsp;Sara Khor PhD,&nbsp;Ashok Reddy MD, MSc,&nbsp;Anna Morenz MD, MS,&nbsp;Karin Nelson MD, MSHS,&nbsp;Nkem Akinsoto MSc,&nbsp;E. Sally Lee PhD,&nbsp;Susan Onstad BA,&nbsp;Edwin S. Wong PhD","doi":"10.1002/cncr.35734","DOIUrl":"10.1002/cncr.35734","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer screening (BCS) inequities are evident at national and local levels, and many health systems want to address these inequities, but may lack data about contributing factors. The objective of this study was to inform health system interventions through an exploratory analysis of potential multilevel contributors to BCS inequities using health system data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors conducted a cross-sectional analysis within a large academic health system including 19,774 individuals who identified as Black (<i>n</i> = 1445) or White (<i>n</i> = 18,329) race and were eligible for BCS. They evaluated individual-level, provider-level, and clinic-level factors. They conducted logistic regression and Blinder-Oaxaca (BO) decomposition analyses to quantitatively estimate the contribution of factors to the mean difference in BCS outcomes between the two racialized groups. They calculated average marginal effects (AME) for the logistic regression models representing the estimated additive probability of receiving BCS in the Black versus White group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>BCS was completed in 63.7% of Black and 71.7% of White individuals (AME, –0.08; 95% confidence interval (CI), –0.10 to –0.04; <i>p</i> &lt; .001). In the BO decomposition, observed factors explained 13.3% difference in BCS. Lower patient portal use among Black versus White patients had the greatest estimated contribution to the BCS inequity (4.6 percentage points; 95% CI, 3.0–6.2).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Racialized group differences in patient portal use had the greatest estimated contribution to the explained difference in BCS between Black and White individuals. Patient portal use promotion could be considered as a part of multifaceted health system efforts to address BCS inequities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center cohort","authors":"Camilla Nero MD, PhD,&nbsp;Rita Trozzi MD,&nbsp;Federica Persiani MSc,&nbsp;Simone Rossi MSc,&nbsp;Luca Mastrantoni MD,&nbsp;Simona Duranti MD,&nbsp;Floriana Camarda MD,&nbsp;Ilenia Marino PharmD,&nbsp;Luciano Giacò PhD,&nbsp;Tina Pasciuto EngD, PhD,&nbsp;Maria De Bonis PhD,&nbsp;Martina Rinelli PhD,&nbsp;Emanuele Perrone MD,&nbsp;Flavia Giacomini PharmD,&nbsp;Domenica Lorusso MD, PhD,&nbsp;Alessia Piermattei MSc,&nbsp;Gianfranco Zannoni MD, PhD,&nbsp;Francesco Fanfani MD, PhD,&nbsp;Giovanni Scambia MD,&nbsp;Angelo Minucci PhD","doi":"10.1002/cncr.35731","DOIUrl":"10.1002/cncr.35731","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To date, 11 DNA polymerase epsilon (<i>POLE</i>) pathogenic variants have been declared “hotspot” mutations. Patients with endometrial cancer (EC) characterized by <i>POLE</i> hotspot mutations (<i>POLE</i>mut) have exceptional survival outcomes. Whereas international guidelines encourage deescalation of adjuvant treatment in early-stage <i>POLE</i>mut EC, data regarding safety in <i>POLE</i>mut patients with unfavorable characteristics are still under investigation. On the other hand, the spread of comprehensive genome profiling programs has underscored the need to interpret <i>POLE</i> variants not considered to be hotspots.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study provides a comprehensive analysis of 596 sequenced patients with EC. The genomic landscape of <i>POLE</i>mut EC was compared with cases harboring nonhotspot <i>POLE</i> mutations within the exonuclease domain. Additionally, the genomic characteristics of multiple classifiers, as well as those exhibiting unfavorable histopathological and clinical features, were examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>No significant genomic differences were observed among patients with <i>POLE</i>mut EC when comparing multiple classifiers to not-multiple classifiers or those with unfavorable clinical features. However, the tumor mutational burden differed in both comparisons, whereas the percentage of C&gt;G mutations only differed in the comparison based on clinical features. Specific <i>POLE</i> mutations, even if not considered to be hotspots, have genomic features comparable to <i>POLE</i>mut.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present findings confirm the absence of significant genomic differences among <i>POLE</i>mut patients regardless of multiple-classifier status or association with high-risk clinical features. Prognostic data will be essential to elucidate the clinical significance of <i>POLE</i> mutations not classified as hotspots that exhibit genomic characteristics similar to those in <i>POLE</i>mut patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer","authors":"Sarah M. Temkin MD","doi":"10.1002/cncr.35735","DOIUrl":"10.1002/cncr.35735","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!","authors":"Ahmet Emre Eşkazan MD","doi":"10.1002/cncr.35737","DOIUrl":"10.1002/cncr.35737","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}